Infectious disease
One day after Moderna announced its COVID-19 vaccine candidate has moved into Phase II testing, Chief Executive Officer Stéphane Bancel laid out the bad news – if it works, there won’t be enough of the vaccine to be quickly distributed across the globe.
The research was published in the New England Journal of Medicine on Thursday, May 7.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
The partnership is aimed at creating antibody products that could act as a “protective shield” against infection by the virus that causes COVID-19, SARS-CoV-2.
To date, 10 plasma companies globally have joined the CoVIg-19 Plasma Alliance, founded to accelerate development of a plasma-derived hyperimmune globulin therapy against COVID-19.
As the world continues to grapple with the effects of the COVID-19 pandemic, healthcare analysts are starting to wonder how the outbreak will impact drug development.
The actual death toll for COVID-19 won’t be calculable for some time, but there are early indications that it may be significantly lower than calculations of deaths per confirmed cases lead one to believe.
Stéphane Bancel, Moderna’s chief executive officer, said the Phase II study is a crucial step in advancing the vaccine candidate as the company looks toward the goal of moving into Phase III.
Ansun Pharmaceuticals used its influenza research data to dive into attempts to develop a treatment for COVID-19. DAS181 is it’s potential candidate for COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
PRESS RELEASES